Form 4: Halozyme Director Receives Annual Equity Grant
Director Equity Compensation Disclosure
Director Jeffrey William Henderson received an annual grant of 3,796 restricted stock units and 6,040 stock options as part of the company's director compensation program.
Summary
- Director Jeffrey William Henderson was granted 3,796 restricted stock units (RSUs) on May 5, 2026.
- The director also received an option to purchase 6,040 shares of common stock at an exercise price of $65.87.
- Both the RSU and option grants are scheduled to vest in full on the earlier of May 5, 2027, or the date of the next annual meeting of stockholders.
- Following these transactions, the director's total beneficial ownership of common stock is 36,572 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.
Positives
- The equity grants align the director's interests with those of shareholders through long-term incentive compensation.
Negatives
- The issuance of additional equity results in minor dilution to existing shareholders.
Risks
- None identified; this is a standard compensatory filing.
Future Outlook
The grants are subject to standard vesting conditions tied to the director's continued service through May 2027 or the next annual meeting.
Industry Context
StockSavvy.ai notes that this filing represents routine corporate governance activity, consistent with standard practices for publicly traded biotechnology companies to incentivize board members.
Comparison to Industry Standards
- The use of annual RSU and option grants for board members is a standard practice among mid-cap biotechnology firms.
- Vesting periods of one year are typical for director equity compensation in the U.S. market.
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity grants on May 5, 2027, or the date of the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Date of the equity grant transaction. |
| 05/07/2026 | Date the Form 4 was filed. |
| 05/05/2027 | Vesting date for the RSU and option grants. |
| 05/05/2036 | Expiration date for the stock options. |
Keywords
Halozyme Therapeutics, HALO, Form 4, Director Compensation, Insider Transaction, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.